SWK HOLDINGS DL-,001 Logo
US78501P2039
A140F1
SWKH

SWK HOLDINGS DL-,001

A carregar cotações...

Previsão

Comprar
  1
Manter
  0
Vender
  0

  • SWK Holdings merges with Runway Growth Finance and is delisted by Nasdaq

    SWK Holdings completed its merger with Runway Growth Finance and became a wholly owned subsidiary of Runway. Shareholders could elect to receive 1.7264 Runway common shares per SWK share or $20.59 in cash; Runway issued about 6.33 million shares and paid $173.54 million in cash. SWK filed for the delisting of its common shares and the suspension of SEC reporting obligations, all incumbent executives resigned, outstanding liabilities were fully repaid, and bond terms were adjusted to comply with the Investment Company Act. » Mais em de.investing.com


  • SWK Holdings: full repayment of loan to Elutia received after asset sale

    SWK Holdings reports the full repayment of a loan to Elutia of USD 27.8 million, including principal, exit fees and accrued interest. The payment follows Elutia’s sale of its BioEnvelope business to Boston Scientific for USD 88.0 million. SWK says the receipt exceeds the loan’s net carrying value under GAAP and expects additional income from accelerated exit fees and the release of risk reserves. SWK also beat earnings expectations in Q2 2025 with earnings per share of USD 0.38. » Mais em de.investing.com


  • SWK Holdings beats Q2 earnings forecast, stock falls after results

    SWK Holdings reported Q2 2025 EPS of $0.38, topping the $0.24 estimate. Cost cuts and asset sales produced GAAP pre-tax income of $4.6 million and net income of $3.5 million. The company paid $49 million in dividends, sharply reduced operating expenses and expects transitions in Q3 related to the sale of "Mod three." Despite the positive results, the stock fell in after-hours and pre-market trading, which investors say reflects concerns about the strategic realignment and regulatory risks. » Mais em de.investing.com

Em 2025, SWK HOLDINGS DL-,001 já distribuiu € 3,56 em dividendos. A última distribuição ocorreu em maio de 2025.

Dados financeiros da empresa

No último trimestre, SWK HOLDINGS DL-,001 registou receitas de € 6,81 mi e um ganho líquido de -€ 16,52 mi
(EUR) dezembro de 2025
YoY
Receitas 6,81 mi -
Ganho bruto 6,5 mi -
Ganho líquido -16,52 mi -
EBITDA 354,57 mil -

Dados fundamentais

Métrica Valor
Capitalização bolsista
€ 167,54 mi
Número de ações
12,1 mi
Máximo/mínimo de 52 semanas
€ 15,59 - € 10,93
Dividendos Não
Beta
0,30
PER (PE Ratio)
-75,71
PEG (PEG Ratio)
0,64
P/VC (PB Ratio)
0,82
P/V (PS Ratio)
4,72

Perfil da empresa

SWK Holdings Corporation ist ein Spezialfinanzierungsunternehmen, das sich auf den Gesundheitssektor konzentriert. Das Unternehmen ist in zwei Segmenten tätig: Finanzforderungen und pharmazeutische Entwicklung. Das Unternehmen bietet maßgeschneiderte Finanzierungslösungen für eine Reihe von Life-Science-Unternehmen, darunter Unternehmen aus den Bereichen Biotechnologie, Medizintechnik, medizinische Diagnostik und verwandte Instrumente, Tiergesundheit und Pharmazie, sowie für Institutionen und Erfinder. Darüber hinaus bietet das Unternehmen institutionellen Kunden nicht-diskretionäre Anlageberatungsdienste in Form von separat verwalteten Konten für Investitionen in die Life-Science-Finanzierung an. Darüber hinaus ist das Unternehmen über die Peptelligence-Plattform in der pharmazeutischen Entwicklung, Formulierung und Herstellung sowie im Lizenzierungsgeschäft tätig. Zu seiner Produktpipeline gehört Ovarest, eine orale Leuprolid-Tablette zur Behandlung endokriner Erkrankungen. Das Unternehmen war früher als Kana Software, Inc. bekannt und änderte im Dezember 2009 seinen Namen in SWK Holdings Corporation. SWK Holdings Corporation wurde 1996 gegründet und hat seinen Hauptsitz in Dallas, Texas.

Nome
SWK HOLDINGS DL-,001
CEO
Jody. D Staggs
Sede Dallas, tx
EUA
Site
Setor
Indústria
Indústria
Transporte terrestre
Entrada em bolsa
23/09/1999
Colaboradores 24

Símbolos de ticker

Bolsa Símbolo
NASDAQ
SWKH
🍪

Parqet  utiliza cookies. Saber mais